First-line treatment options for advanced leiomyosarcoma evaluated by propensity‑score matching
The study evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as first‑line therapies for advanced leiomyosarcoma, reporting progression‑free survival, overall survival, and overall response rate outcomes.
Understanding which chemotherapy backbone confers superior disease control informs clinical decisions for patients with advanced leiomyosarcoma, a sarcoma subtype with limited prospective data.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine—A Systematic Review
- Leiomyosarcoma
- Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
- Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival
- Immunotherapy-based salvage therapy in advanced soft tissue sarcoma after first-line chemotherapy: a retrospective single-center analysis with emphasis on undifferentiated pleomorphic sarcoma